Related Experiment Videos
Hepatitis C: seven years after the discovery of the causative agent
C Verslype1, W Suwandhi, C Clarysse
1Afdeling Lever- en pancreasziekten, Dienst Inwendige Geneeskunde, Universitaire Ziekenhuizen Gasthuisberg, Leuven.
Insights
Hepatitis C virus (HCV) causes liver and other diseases. While interferon alone is insufficient for viral eradication, combining it with ribavirin shows promise for treating HCV infection.
Area of Science:
- Virology
- Hepatology
- Epidemiology
Background:
- The discovery of the hepatitis C virus (HCV) in 1989 revealed its role in diverse liver and extrahepatic pathologies.
- HCV's genetic heterogeneity presents significant challenges for epidemiological studies, diagnostics, and therapeutic strategies.
Purpose of the Study:
- To summarize the impact of hepatitis C virus (HCV) discovery.
- To highlight the challenges posed by HCV genetic diversity.
- To review current treatment approaches for HCV infection.
Main Methods:
- Review of diagnostic assays for HCV detection.
- Analysis of epidemiological data on HCV prevalence and genetic variation.
- Evaluation of treatment outcomes for interferon-based therapies.
Main Results:
- Sensitive diagnostic assays confirm HCV's association with numerous liver and extrahepatic conditions.
- HCV's genetic diversity complicates epidemiological tracking and the development of effective treatments and vaccines.
- Interferon monotherapy has limited efficacy for viral eradication.
Conclusions:
- Combination therapy, particularly interferon with ribavirin, offers a more promising outlook for treating hepatitis C virus infection compared to interferon alone.
Abstract:
Following the discovery in 1989 of the hepatitis C virus (HCV), sensitive and specific diagnostic assays have shown the involvement of this RNA virus in a myriad of liver disease and extrahepatic pathology. The genetic heterogeneity of HCV is an exciting challenge in the field of epidemiology, diagnosis, treatment and vaccine development. Although viral eradication has not been achieved in the majority of patients by using interferon as single agent, the combination with ribavirin seems to have a better outlook.